The Prevalence of Ureaplasma Urealyticum and Mycoplasma Genitalium in Patients with Prostate Cancer in Shohada Hospital in Tehran, Iran
Novelty in Biomedicine,
Vol. 3 No. 2 (2015),
12 April 2015
,
Page 73-78
https://doi.org/10.22037/nbm.v3i2.6641
Abstract
Background: Prostate cancer (PCa) is an important health problem in the aging male population in the world. It is the third most common cancer in the world. Despite of its importance, relatively little is known about its etiology. Sexually transmitted infections (STI) and urogenital pathogens such as Mycoplasma and Ureaplasma, have been proposed as a risk factor for prostate cancer development. This study aimed at detecting the prevalence of Ureaplasma urealyticum (U. urealyticum) and Mycoplasma genitalium (M. genitalium) in PCa and the controls group with benign prostate hyperplasia (BPH) in Shohada hospital.Materials and Methods: A total of 124 paraffin-embedded prostate tissues (62 PCa patients and 62 controls with BPH) were included in this study. The subjects'specimens were investigated by the polymerase chain reaction method for the presence of U. urealyticum and M. genitalium DNA.
Results: U. urealyticum was detected by standard PCR in 1.61% of the 62 PCa patients and there was no DNA U. urealyticum in the 62 controls with BPH. No M. genitalium was detected by standard PCR in the prostates of 124 paraffin-embedded prostate tissues.
Conclusion: According to our results, there is no association between M. genitalium and U.urealyticum with PCa. We recommend further studies using a large sample to determine role of Ureaplasma and Mycoplasma in PCa because understanding the role of infectious agents on PCa might be useful for developing new therapeutic approaches and prevention of PCa.
- Ureaplasma urealyticum
- Mycoplasma genitalium
- Prostate Cancer
- benign prostate hyperplasia
- paraffin-embedded prostate tissues.
How to Cite
References
Bracarda S, Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, et al. Cancer of the prostate. Crit Rev Oncol Hematol. 2005;56(3):379–96.
Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-6.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J. Changing trends of prostate cancer in Asia. Aging Male. 2004;7(2):120-32.
Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. Int J Urol. 2007;14(5):406-11.
Safarinejad MR. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran. Ann Oncol. 2006;17(7):1166-71.
Bracarda S, Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, et al. Cancer of the prostate. Crit Rev Oncol Hematol. 2005;56(3):379–96.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7.
de Martel C, Franceschi S. Infections and cancer: Established associations and new hypotheses. Crit Rev Oncol Hematol. 2009;70(3):183-94.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
Sfanos KS, Isaacs JT. The "infectious" nature of human prostate cancer: a cautionary note. Oncotarget. 2011;2(4):281-3.
Barykova YA, Logunov DY, Shmarov MM, Vinarov AZ, Fiev DN, Vinarova NA, et al. Association of Mycoplasma hominis infection with prostate cancer. Oncotarget. 2011 ;2(4):289-97.
Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology. 2002;13(1):72-9.
Erturhan SM, Bayrak O, Pehlivan S, Ozgul H, Seckiner I, Sever T, et al. Can mycoplasma contribute to formation of prostate cancer?. Int Urol Nephrol. 2013;45(1):33-8.
Taylor ML, Mainous AG, 3rd, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med. 2005;37(7):506-12.
Urbanek C, Goodison S, Chang M, Porvasnik S, Sakamoto N, Li C-z, et al. Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer. BMC Cancer. 2011;11:233.
Ajello L, Hay Rj, Murray P, Funke G, editors. Topley & Wilsonʼs microbiology and microbial infections. 10th ed. London: Hodder Headline Group. 2005.
Gong M, Meng L, Jiang B, Zhang J, Yang H, Wu J, et al. p37 from Mycoplasma hyorhinis promotes cancer cell invasiveness and metastasis through activation of MMP-2 and followed by phosphorylation of EGFR. Mol Cancer Ther. 2008;7(3):530-7.
Jiang S, Zhang S, Langenfeld J, Lo SC, Rogers MB. Mycoplasma infection transforms normal lung cells and induces bone morphogenetic protein 2 expression by post‐transcriptional mechanisms. J Cell Biochem. 2008;104(2):580-94.
Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, et al. Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One. 2009;4(9):e6872.
Rogers MB. Mycoplasma and cancer: in search of the link. Oncotarget. 2011;2(4):271-3.
Vande Voorde J, Sabuncuoğlu S, Noppen S, Hofer A, Ranjbarian F, Fieuws S, et al. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine. J Biol Chem. 2014;289(19):13054-65.
Ravich A, Ravich R. Prophylaxis of cancer of the prostate, penis, and cervix by circumcision. New York State journal of medicine. 1951;51(12):1519-20.
Huang W-Y, Hayes R, Pfeiffer R, Viscidi RP, Lee FK, Wang YF, et al. Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2374-81.
Sutcliffe S, Giovannucci E, Gaydos CA, Viscidi RP, Jenkins FJ, Zenilman JM, et al. Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1573-80.
Bakare R, Oni A, Umar U, Kehinde A, Fayemiwo S, Fasina N. Ureaplasma urealyticum as a cause of non-gonococcal urethritis: the Ibadan experience. Niger Postgrad Med J. 2002;9(3):140-5.
Ross J, Jensen J. Mycoplasma genitalium as a sexually transmitted infection: implications for screening, testing, and treatment. Sex Transm Infect. 2006;82(4):269-71.
Salari M, Karimi A. Prevalence of Ureaplasma urealyticum and Mycoplasma genitalium in men with non-gonococcal urethritis. East Mediterr Health J. 2003;9(3):291-5.
Yeganeh O, Jeddi-Tehrani M, Yaghmaie F, Kamali K, Heidari-Vala H, Zeraati H, et al. A Survey on the Prevalence of Chlamydia Trachomatis and Mycoplasma Genitalium Infections in Symptomatic and Asymptomatic Men Referring to Urology Clinic of Labbafinejad Hospital, Tehran, Iran. Iran Red Crescent Med J. 2013;15(4):340-4
Zeighami H, Peerayeh SN, Safarlu M. Detection of Ureaplasma urealyticum in semen of infertile men by PCR. Pak J Biol Sci. 2007;10(21):3960-3.
Drott JB. The Role of Microorganisms in Prostate Cancer Development. Sweden: Umea university; 2012.
Holst E. Reservoir of four organisms associated with bacterial vaginosis suggests lack of sexual transmission. J Clin Microbiol. 1990;28(9):2035–9.
Keay S, Zhang CO, Baldwin BR, Alexander RB. Polymerase chain reaction amplification of bacterial 16RNA genes in prostate biopsies from men without chronic prostatitis. Urology. 1999;53(3):487-91.
Hrbacek J, Urban M, Hamsikova E, Tachezy R, Eis V, Brabec M, et al. Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. BMC cancer. 2011;11(1):53.
- Abstract Viewed: 829 times
- PDF Downloaded: 505 times